Browse the evidence

Meals from non-chain restaurants contained 16% more energy than national food database information for equivalent meals.

Practitioners should be cautious of relying on national food database information for meal energy content.

The iDiet does not recommend increasing exercise at the beginning of the program.

Practitioners should note that the iDiet's initial focus is on dietary changes rather than exercise.

Observational studies generally report positive associations between dietary energy density (ED) and BMI, risk for overweight/obesity or weight gain.

Practitioners should consider the impact of dietary energy density on weight management.

Longer-term randomized clinical trials suggest that reducing the ED of diets consumed ad libitum may promote modest weight loss.

Modifying dietary energy density may aid in weight loss efforts over time.

The stated energy values of restaurant foods are frequently inaccurate, with measured energy on average not different from stated values corrected for metabolizable energy factors (+7±43%, P=0.57).

Practitioners should be cautious when relying on stated energy values from restaurant menus.

Items with low stated energy (<600 kcal) contained more energy than stated compared to those with high energy (≥600 kcal) (+5% vs. −8%, P=0.05).

Low-calorie menu items may be misleadingly high in actual energy content.

Whole grain diets led to a greater fecal energy content increase of 96 ± 18 kcal/d compared to refined grains.

Higher fecal energy content in whole grain diets may indicate improved energy utilization.

Most participants in the PURE study consumed fewer than the recommended five daily portions of fruits and vegetables.

Efforts should be made to encourage higher fruit and vegetable consumption among populations.

The database contains 821 unique publications linking dietary fibers to health outcomes.

Researchers can access a large body of evidence on dietary fibers and health outcomes.

The majority of studies in the database were randomized controlled trials.

The database is built on high-quality evidence from randomized trials.

Adherence to vegan and WFPB diets for ≥2 years is associated with lower BMI compared to <2 years.

Long-term adherence to vegan and WFPB diets may enhance weight loss outcomes.

During the caloric restriction (CR) period, the mean percentage of adequate nutrient intakes was higher compared to baseline in all CR groups except Wash U.

Practitioners can expect that participants on CR may improve their nutrient intake adequacy.

Intakes of 7 nutrients, including protein, were adequate at baseline and remained so during caloric restriction.

Practitioners can note that certain nutrient levels can be maintained during CR.

Some patients may require weight loss beyond what lifestyle and behavioral modification can achieve.

Recognize that some patients may need additional interventions beyond lifestyle changes.

A ≥15% BMI reduction was associated with a 33% reduction in group health insurance payments at year 1.

Employers may see significant healthcare cost savings by supporting weight loss programs for employees.

Employees who lost ≤5% BMI had a 10% reduction in health expenditures.

Even modest weight loss can lead to some healthcare cost reductions.

Obesity is a chronic disease with significant physical and psychological impairments.

Practitioners should recognize obesity as a serious chronic condition requiring comprehensive management.

There is an urgent need for a structured, customized and evidence-based clinical practice guideline for the management of obesity in Bangladesh.

Practitioners should advocate for and implement structured guidelines for obesity management.

Ultrasonography is a reliable and affordable tool for measuring fat and muscle mass.

Practitioners can consider ultrasonography for better assessment of body composition in patients.

The current Russian clinical guidelines for the treatment of obesity include drugs such as orlistat, sibutramine, and liraglutide.

Clinicians should be aware of the current guidelines when prescribing treatments for obesity.

There is a need to expand existing clinical recommendations for the treatment of patients with obesity.

Healthcare providers should consider integrating new pharmacotherapies into their treatment plans for obesity.

MR-O and Conv-O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence.

Both formulations can be considered equally effective in increasing fecal fat excretion.

The new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O.

MR-OA can be expected to function similarly to Conv-O in promoting fat loss.

Recent studies highlight the efficacy of diabetic agents and other novel therapies in shaping obesity-associated hypertension management guidelines.

Healthcare providers should consider incorporating diabetic agents and novel therapies into treatment plans.